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myocardial ischemia-reperfusion injury studies
Paulus Wohlfart1*, Wolfgang Linz1, Thomas Hübschle1, Dominik Linz2, Jochen Huber1,3, Sibylle Hess1,
Daniel Crowther1, Ulrich Werner1 and Hartmut Ruetten1Abstract
Background: Lixisenatide is a glucagon-like peptide-1 analog which stimulates insulin secretion and inhibits
glucagon secretion and gastric emptying. We investigated cardioprotective effects of lixisenatide in rodent models
reflecting the clinical situation.
Methods: The acute cardiac effects of lixisenatide were investigated in isolated rat hearts subjected to brief
ischemia and reperfusion. Effects of chronic treatment with lixisenatide on cardiac function were assessed in a
modified rat heart failure model after only transient coronary occlusion followed by long-term reperfusion. Freshly
isolated cardiomyocytes were used to investigate cell-type specific mechanisms of lixisenatide action.
Results: In the acute setting of ischemia-reperfusion, lixisenatide reduced the infarct-size/area at risk by 36% ratio
without changes on coronary flow, left-ventricular pressure and heart rate. Treatment with lixisenatide for 10 weeks,
starting after cardiac ischemia and reperfusion, improved left ventricular end-diastolic pressure and relaxation time
and prevented lung congestion in comparison to placebo. No anti-fibrotic effect was observed. Gene expression
analysis revealed a change in remodeling genes comparable to the ACE inhibitor ramipril. In isolated
cardiomyocytes lixisenatide reduced apoptosis and increased fractional shortening. Glucagon-like peptide-1
receptor (GLP1R) mRNA expression could not be detected in rat heart samples or isolated cardiomyocytes.
Surprisingly, cardiomyocytes isolated from GLP-1 receptor knockout mice still responded to lixisenatide.
Conclusions: In rodent models, lixisenatide reduced in an acute setting infarct-size and improved cardiac function
when administered long-term after ischemia-reperfusion injury. GLP-1 receptor independent mechanisms
contribute to the described cardioprotective effect of lixisenatide. Based in part on these preclinical findings
patients with cardiac dysfunction are currently being recruited for a randomized, double-blind, placebo-controlled,
multicenter study with lixisenatide.
Trial registration: (ELIXA, ClinicalTrials.gov Identifier: NCT01147250)
Keywords: Lixisenatide, GLP1-receptor agonist, Diabetes, Macrovascular risk, Cardioprotection, Myocardial ischemia-
reperfusion, Cardiac dysfunction, Pre-clinical modelsBackground
Type 2 diabetes is a major health problem world-wide. In
2010, global prevalence of diabetes had reached 285 mil-
lions according to the International Diabetes Federation
and is expected to increase by over 50% to 552 million by
2030 [1]. Disease progression is characterized by insulin re-
sistance in association with relative insulin deficiency and* Correspondence: Paulus.Wohlfart@sanofi.com
1Sanofi R&D Diabetes Division, Industriepark Hoechst, H825, 65926, Frankfurt/
Main, Germany
Full list of author information is available at the end of the article
© 2013 Wohlfart et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhyperglycemia. Type 2 diabetes confers about a two-fold
excess risk for a wide range of vascular diseases, indepen-
dently from other conventional risk factors [2]. Available
anti-diabetic drug classes have very limited or no docu-
mented benefit on cardiovascular outcome. Therefore,
there is a high need for new anti-diabetic drugs that not
only improve glycaemic control but also cardiovascular out-
come in type 2 diabetes mellitus (T2DM) patients.
New therapies based on the incretin hormone glucagon-
like peptide-1 (GLP-1) are currently tested in clinical stu-
dies on their ability not only to improve the metabolicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vascular risk. Additional GLP-1 effects beyond glycaemic
control have been postulated based on the observation
that the G-protein coupled receptor for GLP-1 (GLP1R) is
expressed in many other organs and cell types including
cardiovascular tissues (for review see [3,4]). GLP-1 in-
fusion resulted in direct vascular relaxation assessed by
flow-mediated vasodilation [5]. When added to standard
therapy in patients with acute myocardial infarction and
successful angioplasty, a 3d long infusion of GLP-1 was
safe, well-tolerated and improved regional and global left
ventricular function [6]. Chronic infusion of GLP-1 signifi-
cantly improved left ventricular function, functional sta-
tus, and quality of life in patients with severe heart failure
[7]. Despite these promising cardiovascular effects, the
therapeutic potential of GLP-1 is limited mainly because of
its short half-life by rapid breakdown through dipeptidyl-
peptidase-4 [8].
To overcome this hurdle exenatide and liraglutide have
been introduced as more stable peptidic GLP-1 receptor
agonists. Both share amino acid sequence homology to
GLP-1 (53% and 97%) and display prolonged half-life in
humans allowing twice daily or once-daily dosing. A third
analog, lixisenatide is a new potent and selective peptidic
GLP-1 receptor agonist for once daily s.c. injection cur-
rently in late stage clinical development. European market
approval was recently granted under the trade name
Lyxumia. In animal models of diabetes lixisenatide im-
proved basal blood glucose and metabolic dysfunction
with a rapid onset and sustained duration of action,
prevented the deterioration of pancreatic responsiveness,
delayed gastric emptying and reduced food intake [9].
Dose-dependent effects of lixisenatide in T2DM patients in-
adequately controlled with metformin were demonstrated in
a randomized, double-blind, placebo-controlled trial [10].
Despite currently ongoing cardiovascular outcome stud-
ies in more than 26,000 T2DM patients directly treated
with exenatide, liraglutide, or lixisenatide, basic mechanis-
tic questions regarding the cardiac mode of action of these
GLP-1 receptor agonists remain puzzling. All analogs have
been tested in only a limited set of pre-clinical cardiovas-
cular studies, and here with a strong focus on infarct size
reduction and acute cardioprotection [11-13]. So far none
of the GLP-1 analogs has been administered in chronic
studies only after the onset of myocardial infarction.
Hence the efficacy on cardiac remodeling beyond an acute
anti-ischemic effect with infarct size reduction is not clear.
Finally specificity of expression measurements of GLP1R
in cardiac tissues has been recently challenged. Some
GLP-1 peptide analogs exert GLP-1 receptor independent
effects in the myocardium [14].
Here, we first investigated the acute effects of lixisenatide
on acute infarct-size reduction in an isolated Langendorff
heart preparation. In a second chronic rat study, with atransient ischemia setting designed to match closer to the
clinical situation, lixisenatide administration was started
clearly after the acute damage. A clinically established ACE
inhibitor, ramipril, served as calibrator in this study proto-
col. In addition several mechanistic and cellular studies
were performed to spread light on underlying signaling
pathways and molecular mechanisms.
Methods
All animal studies conformed to the German law for the
protection of animal guidelines and the guide for the
care and use of laboratory animals published by the US
National Institutes of Health (NIH Publications No 85–
23, revised 1996) as well as to Sanofi-Ethical Committee
guidelines. Approval was granted by a local animal stud-
ies ethic review board.
Specific materials
Ramipril and lixisenatide were synthesized in chemical
departments of Sanofi.
The peptide sequence of lixisenatide is as follows:
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-
Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-
Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-
Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2.
For animal studies, lixisenatide was freshly dissolved
in a sodium acetate buffer consisting of sodium acetate
trihydrate (3.5 mg/mL), glycerol (85%, 18 mg/mL), L-
methionine (3 mg/mL), and m-Cresol (2.7 mg/mL).
Ramipril was mixed in chow at a concentration of
20.8 ppm resulting in a dose of 1 mg/kg/d. GLP-1 (7–
36) amide and GLP-1 (9–36) amide were obtained from
Bachem and used according to the manufacturer’s
recommendations.
Acute ischemia-reperfusion study in isolated rat hearts
Wistar rats (250-300 g) were heparinized (1000 U/kg) and
then anaesthetized with pentobarbital-sodium (NarcorenW,
160 mg/kg i.m.). The heart was quickly excised and placed
in ice-cold & filtered Krebs-Henseleit buffer consisting of
118 mM NaCl, 2.5 mM CaCl2, 4.7 mM KCL, 24.9 mM
NaHCO3, 1.2 mM KH2PO4, 10 mM Glucose, 2 mM
sodium pyruvate, and 1.6 mM MgSO4 adjusted to pH
7.5 and gassing with 95% O2/ 5% CO2. Following a
stabilization period of 15 min, the left anterior descending
artery (LAD) was occluded for 45 min, then re-opened and
the hearts reperfused for 120 min. Lixisenatide (0.3 nM)
was compared to placebo treatment in respective groups
of n=10-11 hearts. Continuous treatments were started
10 min before occlusion till the end of the 120 min reper-
fusion period. During the entire experiment, cardiac
hemodynamics were recorded, specifically left ventricular
pressure (LVP), contractility (LVdP/dtmax), relaxation
(LVdP/dtmin), coronary flow and heart rate. Finally, infarct
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performed by Evans blue and triphenyltetrazolium chloride
(TTC) staining. Quantification of stained slices was
performed using the Morpho-Expert analysis software
(Explora Nova, LaRochelle, France).
Long-term study in rats after transient cardiac ischemia
and reperfusion
Adult male Wistar rats (9 weeks old, 250-300 g, Harlan)
were anesthetized with a mixture of KetavetW (Ketamine,
66 mg/kg) and DomitorW (medetomidine hydrochloride,
0.090 mg/kg i.m.), intubated endotracheally and venti-
lated with a device (RUS-1301 Universeller Respirator,
Föhr Medical Instruments GmbH, Germany). Body
temperature was controlled and maintained at 37°C by
an infrared bulb. The heart was accessed via left thora-
cotomy. The left coronary artery was isolated by using a
6–0 ProleneTM suture (EthiconW) with a tapered needle.
The suture was tightened over a piece of PE-10 tubing
to induce reversible ischemia for 30 min. Ischemia was
accompanied by pale coloration of LV myocardium.
Thereafter, the suture was released to start reperfusion.
The thorax was closed with 2–0 Vicryl (EthiconW) su-
tures, as well as the skin incision with 2–0 sutures.
Anesthesia was neutralized by injection of AntisedanW
(Atipamezolhydrochlorid, 0.5 mg/kg, i.m.). For pain re-
lief DipidolorW (Piritramid, 3 mg/kg, s.c.) was given.
Once the recovery was complete, the animal was
returned to the rodent animal house facility. One day after
surgery, animals were randomized into three treatment
groups with at least 18 animals per group and consisting
of I/R placebo, I/R ramipril (1 mg/kg/d pressed in chow)
and I/R lixisenatide (10 μg/kg/d s.c.) over 10 weeks. A
fourth group consisted of sham operated animals, without
the myocardial ischemia-reperfusion procedure. After
10 weeks treatment, the animals were anesthetized with
100 mg/kg i.m. pentobarbital-sodium (NarcorenW). Left
ventricular pressure (LVP), left ventricular end-diastolic
pressure (LVedP), dP/dtmax, dP/dtmin, heart rate and tau
Weiss were continuously recorded by a Millar tip catheter
placed into the left ventricle. Finally the heart was arrested
in diastole by infusion of a saturated potassium chloride
solution. Hearts were rapidly excised and weighed (total
heart weight). Thereafter atrial as well as non-cardiac tis-
sues were carefully removed, left-ventricular (LV) and
right-ventricular (RV) weight were measured and the left
ventricle was kept for further evaluation of histology,
fibrosis and gene expression measurements. Left ventricle
containing the papillary muscles was fixed in buffered 4%
paraformaldehyde and embedded in paraffin for histo-
logical evaluation. LV sections at the papillary muscles
level were cut at 5 μm, deparaffinized, rehydrated and
stained with picrosirius red to visualize interstitial and
peri-vascular fibrosis. The percentage of the left ventriclestained for collagen was calculated as the ratio of
picrosirius-red positively stained area over total tissue area
using Morpho Expert image analysis software (Explora
Nova, La Rochelle, France).
Biomarker assessment in the long-term study
A set of biomarkers were assessed using plasma and
serum obtained at the end of the long-term ischemia
reperfusion study. Serum levels of cholesterol, triglyc-
erides, creatinine, urea, glucose and ACE-activity were
determined on a Hitachi 912 analyzer, using the
respective Roche clinical chemistry kits for human
diagnostics.
Serum BNP 32 as a biomarker for rat heart failure was
determined by a commercial ELISA (Phoenix Pharma-
ceuticals, Inc. Karlsruhe, Germany). Serum insulin con-
centrations were determined using a commercial rat
ELISA kit (Mercodia, Upsala, Sweden).
Gene expression studies using left ventricular sections of
the long-term study
RNA was isolated from formalin-fixed and paraffin-
embedded tissues. Using a sharp razor blade each paraffin-
embedded LV block was divided into half separating the
free LV wall part from the septal wall part and 16 consecu-
tively divided slices (10 μm) were collected into Eppendorf
tubes. A specific RNA isolation kit was used according to
the manufacturer’s instructions (RecoverAll Total Nucleic
Acid Isolation Kit, #AM1975, Life technologies, Darmstadt,
Germany). Reverse transcription into cDNA (10μL RNA,
approximately 10 ng/μl) was performed using a high-
capacity kit (cat# 4374966, Life technologies). Then a quan-
titative pre-amplification step consisting of 14 cycles was
included using 4μL cDNA solutions, 4μL target specific
primer pool, and 8μL TaqMan PreAmp MasterMix
(cat# 4391128, Life technologies). The results pre-amplified
solutions were diluted with water and mixed with TaqMan
Universal PCR Master Mix (cat# 4369016, cat# 4374966,
Life technologies) according to the manufacturer’s instruc-
tion. In case of single PCR reaction independent wells were
filled with pre-amplified DNA, specific primers and
master mix. In addition, ports of 384 well format micro-
fluidic cards were filled with 100 μl sample solution,
briefly centrifuged twice for 1,200 rpm and sealed. Each
micro-fluidic card contained 8× 96 genes (93 target genes
and 3 housekeeping genes) listed in the Additional file 1.
Real-time PCR (40 cycles) were performed using a ViiA7
cycler (Life technologies).
Isolation of rodent cardiomyocytes
Ventricular cardiomyocytes were isolated from 250-300 g
male Sprague-Dawley rats as previously described [15]
with some modifications. During retrograde perfusion of
excised hearts Liberase-IV as digesting enzyme was used
Figure 1 Effect of lixisenatide on infarct size and cardiac
function in isolated rat hearts subjected to ischemia (45 min)
and reperfusion (120 min). (A) infarct to risk area ratio, (B) risk
area, and (C, D) selected coronary flow and rate pressure product
immediately after onset of reperfusion (5 min) and at the end of
reperfusion (120 min). *) denotes p < 0.05 versus placebo.
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enzyme was re-circulated for 30 min in Joklik Medium
(Biochrom, Berlin, Germany) additionally buffered with
HEPES (15 mM). Thereafter atria were removed, and
ventricles minced and cut into pieces in Powell’s Medium
(145 mM NaCl, 2.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 15 mM HEPES, 11 mM glucose, pH 7.4) contai-
ning 20 μM CaCl2 and 15 mM 2,3-butanedioneoxime-
diacetylmonoxime (BDM, Fluka Chemie, Germany). After
filtering through a nylon mesh, cells were centrifuged at
30 × g for 4 min. Extracellular calcium was stepwise in-
creased (200 μM, 400 μM, 1 mM) by overall 3 centrifugation
steps (30 × g for 4 min). Finally, the isolated cardiomyocytes
were suspended in fetal calf serum free Joklik medium with
1 mM CaCl2 and 5 mM BDM and plated at a density of
1.5×104 rod-shaped cells per cm2 cultivation area. Two hours
after plating, cultures were washed with basic culture
medium consisting of HEPES-buffered Joklik medium with
5 mM creatinine, 2 mM L-carnithine and 5 mM taurine,
100 IU/ml penicillin, 100 μg/ml streptomycin, 100 μMascor-
bic acid and cytosine-ß-D-arabinofuranoside (10 μM) as
further supplements. A similar isolation protocol was
used for isolation of mouse cardiomyocytes from either
GLP1R knockout mice or age-matched CD1 mice serving aswildtype control. Four mouse hearts were perfused in
parallel and isolates combined thereafter.Measurement of apoptosis and fractional shortening
analysis in cardiomyocytes
In order to determine apoptosis, caspase-3/7 and cell via-
bility were determined in rat cardiomyocytes incubated in
35 mm culture dishes in HEPES-buffered Joklik medium
with either insulin or lixisenatide for 18 h. Caspase-3/7
activity and cell viability were determined in independent
dishes using chemiluminiscence kits (G8092/3 and G7571,
Promega, Madison, USA). Contractile responses of single
cardiomyocytes were measured by an electro-optical mon-
itoring system as described in detail elsewhere [16] with
some minor modifications. Briefly, cells were measured
after a resting period of 24 h in 35 mm culture dishes
(Falcon, type 3001) in modified Tyrode’s solution (145 mM
NaCl, 2.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4,
1.0 mM CaCl2 10 mM HEPES, 10 mM Glucose, pH 7.4).
Single cells were subjected to a biphasic rectangular voltage
ramp from −50 to 50 V with 0.5 ms duration at a frequency
of 0.5 Hz. When the contraction amplitude reached sta-
bility, four contraction cycles were recorded and deter-
mined via standard software. In each batch of isolated
cardiomyocytes at least 18 cells were measured for each
condition and the results finally averaged. Each experiment
was repeated twice on independent cell isolations.Overall data analysis and statistics
Data from each experiment and study were carefully
analyzed using SAS (version 8.2) for SUN 4 via interface
software EverStat V6.0. First, data were analyzed for nor-
mality and for homogeneous variances (Levene). In case
of Gaussian distributions, ANOVA was employed. In
case of heterogeneous variances and/or non-Gaussian
distribution, a Kruskal-Wallis test was used followed by
the Kruskal-Wallis multiple comparisons test versus
Placebo. P-values <0.05 were regarded as statistically
significant. Data are presented as mean ± SEM.
Standard gene expressions analysis was performed
based on the Δc(t) method. Standardization was related
to a geometric mean value of all housekeeping genes
based on the bestkeeper algorithm [17]. A gene expres-
sion level was set as undefined if no amplification was
achieved at maximum cycle time (c(t) > 40). Array Studio
(Omicsoft, V6.1) was used for micro-fluidic card PCR
analysis and subsequent principle component analysis,
hierarchical clustering and generation of heatmaps.
Missing data was imputed using k-nearest neighbors,
method with the missing value replaced by the mean of
the 5 nearest neighbors. For the 2D hierarchical cluster-
ing, Pearson dissimilarity was selected for the distance
metric and complete linkage was used for the tree
Table 1 Effect of long-term treatment with ramipril (I/R ramipril) and lixisenatide (I/R lixisenatide) after transient
ischemia reperfusion injury
Sham I/R Placebo I/R ramipril (1 mg/kg/d p.o.) I/R lixisenatide (10 μg/kg/d s.c.)
Body Weight (g) 441 ± 9 432 ± 9 403 ± 7* 390 ± 6*
Food consumption (mg/kg/d) 73 ± 3 78 ± 2 72 ± 5 79 ± 4
Water consumption (mL/kg/d) 116 ± 3 120 ± 2 168 ± 5* 120 ± 2
Plasma BNP (pg/mL) 112 ± 5* 178 ± 14 113 ± 6* 110 ± 7*
Plasma glucose (mmol/L) 8.8 ± 0.2 8.8 ±0.3 8.6 ± 0.3 8.0 ± 0.4
Plasma triglyceride (mmol/L) 0.61 ± 0.09 0.49 ± 0.05 0.44 ± 0.04 0.47 ± 0.03
Plasma ACE activity [U/L] 186 ± 17 206 ± 37 51 ± 11* 192 ± 10
LVP (mmHg) 118 ± 5* 106 ± 3 97 ± 2* 105 ± 3
LVedP (mmHg) 3.22 ± 0.49* 10.32 ± 1.45 5.11 ± 0.93* 4.52 ± 0.43*
dP/dt max (mmHg/sec) 6695 ± 268* 5023 ± 210 4724 ± 197 5136 ± 243
dP/dt min (mmHg/sec) −6877 ± 373* −4463 ± 206 −4499 ± 184 −4683 ± 278
Heart Rate (beats/min) 324 ± 8 316 ± 6 327 ± 7 308 ± 8
tau Weiss (msec) 8.39 ± 0.45* 15.08 ± 0.75 11.93 ± 0.76* 11.37 ± 0.47*
Heart Weight (g/100 g BW) 0.26 ± 0.01* 0.29 ± 0.01 0.28 ± 0.01 0.28 ± 0.01
Cardiac expansion index 0.29 ± 0.02 0.28 ± 0.04 0.23 ± 0.05 0.30 ± 0.05
Lung Weight (g/100 g BW) 0.44 ± 0.03* 0.63 ± 0.05 0.44 ± 0.02* 0.43 ± 0.02*
Liver Weight (g/100 g BW) 3.31 ± 0.04 3.23 ± 0.06 3.12 ± 0.05 3.02 ± 0.16
Right Kidney Weight (g/100 g BW) 0.30 ± 0.01 0.30 ± 0.01 0.35 ± 0.01* 0.30 ± 0.01
Abbreviations used are brain natriuretic peptide (BNP), left ventricular pressure (LVP), left ventricular end-diastolic pressure (LVedP), myocardial contractility/
relaxation (dP/dtmax, dP/dtmin), heart rate, relaxation time (tau Weiss). Mean values ± SEM are shown. *) indicates p < 0.05 versus the placebo group (I/R injury
without treatment).
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Results
Acute ischemia reperfusion injury in isolated rat hearts
The LAD coronary artery was occluded for 45 minutes
followed by reperfusion for 120 minutes. Treatment
with lixisenatide significantly reduced infarct-size when
starting 10 min prior to end of ischemia (Figure 1). In-
farct area in placebo hearts was 162 ± 12 mm2, and in
lixisenatide treated hearts 98 ± 9 (mean values ± SEM,
n=10-11, p < 0.05). There were no differences between
the different treatment groups regarding left ventricular
total area (543 ± 16 mm2 for placebo versus 505 ± 7 mm2
for lixisenatide treatment) left ventricular risk area
(306 ± 9 mm2 for placebo versus 288 ± 5 mm2 for
lixisenatide treatment). Overall, the ratio of infarct area
to area at risk was reduced by lixisenatide by 36% when
compared to placebo treatment (Figure 1A). The rate
pressure product (LVP x HR) and coronary flow were
not altered during the reperfusion period as shown for 5
and 120 minutes (Figure 1B and C).
Long-term injury induced by a transient ischemia
reperfusion
In order to reveal beneficial effects of lixisenatide long-
term treatment on cardiac remodeling, a study in ratswith transient ischemia and 10 weeks reperfusion was
performed. The major ischemia-reperfusion damage
occurs within the first day after myocardial infarction.
By randomization of infarcted animals to different treat-
ments after the acute damage period, we excluded
potential effects on infarct size as confounding factor.
Main intention of the long-term study was to prove
efficacy on post myocardial infarction induced remodel-
ing and not acute anti-ischemic efficacy.
Body weight but not food consumption was slightly lower
in rats treated for 10 weeks with lixisenatide (10 μg/kg/d)
or the ACE Inhibitor ramipril (1 mg/kg/d p.o.) compared
to I/R placebo group (see Table 1). Ischemia and long-term
reperfusion resulted in cardio-dynamic impairment that
was attenuated by treatment with either lixisenatide or
ramipril. Indeed, increased left ventricular end-diastolic
pressure as a measure for impaired diastolic function, tau
Weiss as a measure for myocardial relaxation, and lung
weight as a measure of congestion, were all significantly
improved towards sham values for the treatment groups
(Figure 2).
Increased serum levels of brain natriuretic peptide
(BNP) were normalized in lixisenatide or ramipril treated
animals. No effect on plasma glucose or triglyceride was
observed. ACE activity was blocked in the ramipril but
not the lixisenatide group (see Table 1). A slight but non-
significant increase in heart weight could be observed in
Figure 2 Effect of long-term treatment with lixisenatide or ramipril after transient ischemia-reperfusion injury: Heart weight. (A), lung
weight (B), left-ventricular end diastolic pressure (LVedP, C) and relaxation time (tau Weiss, D). *) denotes p < 0.05 versus sham and #) p < 0.05
versus placebo.
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tion could be seen using the histologically defined expan-
sion index introduced by Hochmann and Choo (Table 1)
[18]. Left-ventricular wall thickness was reduced by
ischemia-reperfusion and not significantly modified by
treatment groups (Figure 3C). Septal wall thickness was
not altered between any groups. Slightly increased right
ventricular wall thickness was normalized to sham value
by lixisenatide treatment.
A significant increase in left ventricular fibrosis was
observed by the ischemia-perfusion procedure assessed by
picrosirius red staining (Figure 3A and B). Neither
lixisenatide nor ramipril treatment resulted in a decrease
in fibrosis. At the end of the chronic study, we analyzed
the expression of a number of selected genes in slices
taken from infarcted and non-infarcted areas of the hearts.
In the infarct area, remodeling genes like osteopontin and
collagen isoforms were up-regulated by the ischemia re-
perfusion damage. In accordance with the histological
staining expression of those genes was not modulated by
either ramipril or lixisenatide (Figure 3D).
In order to reveal a more global reaction pattern, ex-
pression of 93 specific genes and 3 housekeeping genes
was quantified in RNA isolated from the tissue slices
(n=5 per treatment group and area) by micro-fluidic
card PCR. The 93 genes were pre-selected based on pub-
lished cardiac remodeling data and covered apoptosis,
autophagy, remodeling, and inflammation pathways. A
heat map visualization of these data indicated differential
patterning (Figure 4A). First, the majority of shamtreated samples were linked together in one major clus-
ter (left part of the heatmap). Another major cluster in-
cluded infarct area samples and here two subclusters
from either placebo or lixisenatide/ramipril treatment
(right part of the heatmap). A principle component ana-
lysis (PCA) was performed on the gene expression data
to reduce the complexity of 93 genes expressions within
one sample into independent principal major compo-
nents (Figure 4B). Two major clusters became visible.
Most of the non-infarct regions samples clustered
together with nearly all sham samples. Gene expression
in the infarct regions formed another cluster with 2
subcluster separating all lixisenatide and 3 of 5 ramipril
samples from placebo, respectively. We further performed
a 2 way ANOVA analysis on differentially regulated indi-
vidual genes. Additional file 2 lists all genes with a p-value
of p<0.05 comparing the different treatments and areas.
Lixisenatide and ramipril treatment resulted in the infarct
area in a similar up- or down regulation of only three
genes by a factor greater than 1.5 fold. To reveal
lixisenatide specific gene regulations unbiased Affymetrix
microarray measurements maybe a next useful step.
Effects in isolated rodent cardiomyocytes
To better understand the beneficial effects of lixisenatide,
we performed experiments with lixisenatide on isolated
cardiomyocytes. Longer incubation of rat cardiomyocytes
with either lixisenatide or insulin resulted in a decrease in
caspase-3/7 activity indicating a reduction in cardiomyocyte
apoptosis (Figure 5A). A concentration-dependent increase
Figure 3 Effect of long-term treatment with either lixisenatide or ramipril after transient ischemia-reperfusion injury on heart
morphology. (A) Picrosirius red staining at the papillary muscle level of representative animals, Bar = 5 mm; (B) quantification of left ventricular
fibrotic to total area; (C) thickness of the left ventricular, septal and right ventricular wall; and (D) gene expression analysis by realtime PCR of
selected fibrosis genes. *) denotes p < 0.05 versus sham and #) p < 0.05 versus placebo.
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lixisenatide that was comparable to adrenergic stimulation
with isoprenaline (Figure 5B). This functional response was
partly reversed by brief pre-incubation with the PI-3-kinase
inhibitor wortmannin (see Additional file 3: Figure S3).
Other GLP-1 receptor agonist like exenatide-4 also resulted
in increased fractional shortening (see Additional file 3:
Figure S3). However, the endogenous GLP-1 receptor agon-
ist GLP-1 (7–36)-amide did not elicit significant increaseeven at highest concentrations (Figure 5C). Cardiomyocytes
isolated from both GLP-1 receptor knockout mice and re-
spective wild-type animals (CD1) responded to lixisenatide
(Figure 5D) with an increase in fractional shortening.
Expression of genes involved in the GLP-1-incretin axis
A local GLP-1 release may exist in the heart, potentially
competing with lixisenatide on the GLP-1 receptor. There-
fore we analyzed tissues for the expression of the GLP-1
Figure 4 (See legend on next page.)
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Figure 4 Gene expression patterns 10 weeks after ischemia reperfusion injury performed on all samples and comparing non-infarct
area versus infarct area. (A) Determination of 92 representative genes followed by 2 dimensional hierarchical clustering and visualization as
heatmap. Each sample forms a column and each gene forms a row with the heatmap intensities standardized within each gene. Overall 5
independent samples were measured for each group and two different tissue areas (infarct and non-infarct ventricular tissue) resulting in a final
number of 40 samples. (B) Principle component analysis (PCA) of the same data reflecting the total expression changes into two uncorrelated
principal components.
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degrading proteases, PCSK1, PCSK2 and DPP4 (Figure 6).
Neither GCG, nor PCSK1 or PCSK2 expression could be
observed in cardiac samples ruling out the existence of a
local GLP-1 generation.
In parallel we determined the expression of GLP-1 recep-
tor using two different specific Taqman primer assays span-
ning different exon/intron within the known rat sequence
(Figure 6). Use of both primers assays indicated a similar
strong expression in pancreas, isolated pancreatic islets and
lung, but failed to amplify specifically any signal from car-
diac tissue and cardiomyocytes. It seems that all cardiac tis-
sues lack components of a local incretin system with DPP-
IV being the exception.
Discussion
Since the early 1990s GLP-1 peptides and analogs have
been investigated for treating T2DM because of theirFigure 5 Effect of lixisenatide treatment on apoptosis and contractilit
cardiomyocytes incubated with either insulin or lixisenatide (each at 100 nM
fractional shortening. Isoprenaline (Iso, 1nM) served as positive control. (D).
to lixisenatide. Mean values and SEM are given. In the fractional shortening eability to enhance glucose-dependent insulin secretion. In
addition, GLP-1 agonists are hypothesized to have effects
on the cardiovascular system beyond glycaemic control,
which may be exploited for therapeutic benefit [19,20].
Cardiovascular disease is the leading cause of death in pa-
tients with type 2 diabetes. In a recent prospective cohort
study of one million U.S. adults, diabetes was associated
with a twofold increase in the risk of death from ischemic
heart disease [21]. Concerns about the cardiovascular safety
of anti-diabetic drugs resulted in the FDA recommendation
that the CV risk should be more thoroughly addressed dur-
ing drug development [22]. As a consequence of this new
guideline cardiovascular outcome studies are currently on-
going in more than 26,000 type 2 diabetic patients directly
treated with GLP-1 receptor agonists and more than 40,000
treated with a DPP-IV inhibitors which also may act indir-
ectly via GLP-1. The overall goal of our study was to dem-
onstrate in a pre-clinical set of models cardioprotectivey of isolated cardiomyocytes. (A) Caspase-3/7 activity is reduced in
). (B, C) Lixisenatide (Lixi) but not GLP-1 (6–36)-amide increases
Cardiomyocytes isolated from GLP-1 receptor knockout mice respond
xperiments, n > 18 single cardiomyocytes were measured for each group.
Figure 6 Expression of 5 genes involved in GLP-1 incretin biology in different rat tissues assessed by quantitative Taqman PCR. Two
biologically different samples were analyzed and averaged (shown are mean values and SD). The geometric mean of three housekeeping genes
(GAPDH, Actb and B2M) was used to normalize expression of specific genes using the formula 2^-Δc(t). For detection of GLP1R two different
specific Taqman primer assays were used spanning different part of the receptor mRNA. GLP1R (P1) denotes Rn00562406_m1 and detect exon
3–4. GLP1R (P2) is the label for Rn01640381_m1 which detects a sequence spanning exon 8–9. The term n.a. indicates that no specific
amplification could be achieved at the maximum cycle number (n=40).
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fundament for clinical testing in patients with reduced car-
diac function.
In an acute model of global cardiac ischemia-reperfusion
injury, lixisenatide treatment during the last 10 minutes of
ischemia and during the whole reperfusion period signifi-
cantly reduced infarct size. The observed cardioprotective
effect was not associated with a significant change in car-
diac hemodynamics, as assessed by rate-pressure product
RPP (LVDP x HR), and particularly coronary flow. The re-
sults described here with lixisenatide are consistent to simi-
lar results in previous studies with another GLP1R agonist,
exenatide [11]. Ischemia reperfusion injury is a multifaceted
damage, comprising effects on cardiomyocytes function
and death and endothelial function. Due to the lack of
effect on coronary flow by lixisenatide, we assume a direct
effect on cardiomyocyte function and survival. Sonne and
co-workers found that GLP-1 (9–36) amide, which is the
first breakdown fragment of GLP-1 (7–36) amide but not
a GLP-1 receptor agonist, did not reduce infarct size but
however increased functional recovery of ischemia hearts
[11]. Based on these finding the authors proposed that be-
side the known GLP-1 receptor another hitherto unidenti-
fied receptor could be responsible for effects of GLP-1 like
peptides in rat hearts.
Only a limited numbers of pre-clinical studies have in-
vestigated so far effects of GLP-1 peptides on long-term
consequences after myocardial ischemia and reperfusion.
Using liraglutide, Noyan-Ashraf and coworkers demon-
strated cardioprotection after myocardial infarction in
diabetic and non-diabetic mice [13]. Liu and coworkers
treated rats two weeks after myocardial infarction with
either GLP-1 (7–36) or the exenatide analog AC3174
and noticed improved cardiac function and morphology[23]. In contrast to those previous studies, we performed
only a transient and not permanent ligation of the left
coronary artery in our rat model in order to obtain re-
sults closer to the clinical situation in which almost all
patients with myocardial infarction are reperfused. The
transient ischemia reperfusion protocol resulted in only
moderate changes of systolic function after a long-term
recovery period. LVP and dp/dtmax were slightly reduced
in the ischemia reperfusion group versus sham treated
animals. Ramipril but not lixisenatide normalized LVP
but not dp/dtmax. Major differences were observed for
the active treatments regarding diastolic function, in par-
ticular on left ventricular end diastolic pressure (LVedP)
and the relaxation time tau Weiss. These functional im-
provements occur despite lack of effect on increased car-
diac fibrosis assessed by specific morphological staining
and gene expression analysis. In addition, heart weight
did not significantly differ between the various groups rul-
ing out strong effects on hypertrophy of cardiomyocytes
as potential mode of action. Moreover, we noticed no
effects on plasma glucose and insulin by lixisenatide treat-
ment in this non-diabetic model. Hence, indirect effects
on heart metabolism via glucose uptake may not suffi-
ciently explain the observed improvement in cardiac
function.
A broader gene expression pattern of genes involved
in rat cardiac remodeling delivered two major findings.
First, the myocardial infarction is a major driver of gene
expression changes and drug effects in the non-infarct
regions of infarcted hearts are rather moderate. Second,
lixisenatide and the ACE inhibitor ramipril are similar in
their reaction pattern, indicating activation of more
common protective signaling pathways for both treat-
ments. A principal component analysis supported these
Wohlfart et al. Journal of Translational Medicine 2013, 11:84 Page 11 of 12
http://www.translational-medicine.com/content/11/1/84conclusions. An ANOVA analysis provided a few num-
ber of genes differentially regulated by lixisenatide versus
placebo in the infarct area (see Additional file 2).
Interestingly, lixisenatide was equipotent to GLP-1 and
other GLP-1 receptor analogues on reducing infarct size
in perfused isolated rat hearts. In contrast, lixisenatide at
higher concentrations, but not GLP-1, improved frac-
tional shortening in isolated cardiomyocytes. This might
suggest that lixisenatide displays acute cardioprotection
via the GLP-1 receptor, while effects of lixisenatide on
contractility are mediated by a different signalling path-
way. In line with our findings, Vila Petroff et al. showed
the lack of contractility-promoting effect of GLP-1 in
isolated cardiomyocytes [24]. We supplemented their
findings by demonstrating that even very high concentra-
tions of the GLP-1 peptide, not amenable to rapid degrad-
ation by dipeptidyl-peptidase-IV (DPP4), were ineffective.
Finally, when performing a similar set of experiments on
cardiomyocytes from GLP-1 receptor knockout mice, a
robust response to lixisenatide remained suggesting a
GLP-1 receptor independent effect lixisenatide on the
contractility response.
Lixisenatide displayed beneficial effects in our rodent
models, but GLP-1 receptor mRNA was not detectable
without ambiguity. Two different PCR Taqman probes,
located to different parts of the rat gene, did not reveal
abundant expression of the GLP-1 receptor in rat hearts
and cardiomyocytes, but indicated a strong expression in
other organs like rat pancreas. Overall, controversial
data on the expression of the GLP-1 receptor in mam-
malian cardiac tissues exists. GLP-1 receptor mRNA
expression in human heart samples was detected by an
RNA protection assay [25]. In contrast, using autora-
diography with a radio-labeled GLP-1, no staining was
detected in human heart despite several other organs be-
ing positive for this ligand [26]. An antibody against the
GLP-1 receptor stained in mouse heart several cell types
[27]. Later it was shown that available antibodies against
the GLP-1 receptor display strong cross-reactivity in
cells not expressing the GLP-1 receptor [28]. Hence,
immunostainings should be carefully considered as long
as specificity is not clearly demonstrated. Simultaneously
to immunostainings, Ban et al. detected mRNA for the
GLP1-receptor, using an endpoint PCR with a high
number of amplification cycles followed by specific
hybridization [27]. This methodology does not rule out a
very low expression level in the samples. Bullock and co-
workers used the RNAse protection assay, a more quan-
titative but less sensitive methodology, to assess mRNA
distribution in rat tissues for the GLP-1 receptor. They
could not confirm expression in the rat heart in contrast
to other positive tissues like pancreatic tissues [29].
Currently, we cannot exclude that a GLP1R variant is
expressed in the heart which is not detectable using thetwo different PCR primer assays. In addition, a normal
GLP1R may be expressed in rodent hearts in other cell
types than cardiomyocytes with overall low abundance,
e.g. in resident or invading immune cells. Alternatively,
another receptor, not related in its primary structure to
the GLPR1 may exist in the rat heart that is responsive to
lixisenatide and other GLP-1 analogs, mediating the
cardioprotection seen in our studies. Clearly, further work
needs to be invested here, e.g. testing of lixisenatide and
related GLP-1 like analogs on ligand efficacy of a broad
panel of receptors.
The pre-clinical effects described here provide a ration-
ale for further clinical testing of lixisenatide in patients at
cardiovascular risk. In a first randomized, double-blind,
placebo-controlled, multicenter study patients are cur-
rently being recruited (ELIXA, ClinicalTrials.gov Identi-
fier: NCT01147250). The primary objective of this study
with approximately 6,000 patients is to demonstrate that
lixisenatide can reduce cardiovascular morbidity and mor-
tality compared to placebo in type 2 diabetic patients who
recently experienced an acute coronary syndrome event.
Conclusions
We could demonstrate that lixisenatide induced cardio-
protection in short- and long-term rat models of ischemia-
reperfusion ischemia. Most probably direct effects on
cardiomyocytes independent of the GLP-1 receptor im-
proving function and reducing apoptosis explain best the
cardiac efficacy of this peptidic GLP-1 receptor analog. The
mechanism of the lixisenatide mediated cardioprotection
warrants further investigations.
Additional files
Additional file 1: List of specific Taqman primers used in the
micro-fluidic card analysis.
Additional file 2: Expression analysis of 93 selected genes at the
end of chronic treatments after MI. Normalized abundance data are
given for each treatment and two different heart regions. Slices of the
septum served to determine expression in no-infarct-region. Slices from
the infarcted left ventricular region contain mainly infarcted area. This file
also contains a comparision of up- and downregulated genes between
treatments and compared to the placebo group. Only genes are shown
with a p-value of p<0.05. The upper part consisted of infarcted area, the
lower of non-infarcted area. Upregulation <1.5 fold is indicated by an
underlying orange colour. Down-regulations >1.5 fold are shaded blue.
Additional file 3: (A) Effects of co-inbuation of wortmannin on
lixisenatide induced cardiomyocyte contractility. (B) Comparision of
different GLP-1 like peptides (each at 100 nM) on cardiomyocyte
contractility. *) denotes p<0.05 versus control; #) denotes p<0.05 versus
lixisenatide treatment.
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